A Bioresorbable Injectable Scaffolds for bone tissue regenerative medicine.
Proposal acronym: InBoneGlue
Topic: SMEInst-02-2016-2017: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs
Project ID: 807927
Commercialization of an innovative biodegradable bone filler (InBoneGlue) to be used in the field of Oral surgery, for the alveolar ridge preservation and for the filling of the retroatrial bone defects and Orthopedics surgery for the treatment of bone lesions and defects (complex fracture, bone mass loss due to degenerative diseases, ie. Osteoarthritis, Osteoporosis etc.).
Results: following evaluation by an international panel of independent experts
WAS SCORED AS A HIGH-QUALITY PROJECT PROPOSAL IN A HIGHLY COMPETITIVE EVALUATION PROCESS* as certificate by the Seal of Excellence delivered by the European Commission (19/12/2017)
Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis: BIOFOSTE
Project ID: 718965
COORDINATOR: ISTITUTO DI RICERCA TRASLAZIONALE PER L’APPARATO LOCOMOTORE NICOLA CERULLI – LPMRI – SRL (935361495) – BENEFICIARY: CYANAGEN SRL (998508495) –
OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years.
The clinical manifestations of OA are pain and functional disability that can limit the normal activities of daily life and lead to depression and isolation.
OA assessment is mainly carried out using radiography, which is the gold standard for diagnostic purposes. However this approach has poor sensitivity and diagnosis is obtained only when the articular cartilage has degraded significantly.
Based on the extremely high economic burden, quantified in tens of billions of euro in the world, which will tend to increase in the future years, there is a need to validate OA biomarkers.
In fact, although several proteins and miRNAs have been described as being altered and correlated with OA progression, there are no currently available BIOmarkers for OA diagnosis.
This project concerns the development and clinical validation of a combined panel composed of proteins and miRNAs, which have been found altered in OA patients, combined with a new marker identified by IRTAL and a patented secondary chemiluminescence ELISA enhancer developed by CYANAGEN to ensure a high sensitivity for an early OA diagnosis.
Our final goal is to validate and commercialize an IVD kit that may help the clinicians make an early diagnosis or predict the outcome/prognosis of OA patients, to improve the patients’ quality of daily life while decreasing the related economic losses due to unproductivity, absenteeism, disability and also in terms of surgical procedures and hospitalization resources for the Health care systems.
This project will allow involved SMEs to enter in the IVD market seizing the related business opportunity.
In Phase 1 of the project we will select the optimal biomarkers, determine the market and clinical utility of the diagnostic test.